Nimenrix

Nimenrix

vaccine, meningococcal

Manufacturer:

Pfizer

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Meningococcal polysaccharide serogroups A, C, W-135 & Y conjugate vaccine
Indications/Uses
Active immunisation of individuals from 6 wk against invasive meningococcal diseases caused by Neisseria meningitidis serogroups A, C, W-135 & Y.
Dosage/Direction for Use
IM Primary immunisation Infant from 6 wk to <6 mth 2 doses 0.5 mL each w/ 1st dose given from 6 wk w/ 2 mth interval between doses. Unvaccinated infant from 6 mth to <12 mth 0.5 mL dose given from 6 mth. Childn from 12 mth 0.5 mL single dose. Booster vaccination Infant from 6 wk to <6 mth Booster dose should be given at 12 mth after completion of primary immunisation course. Previously vaccinated infant from 6 mth to <12 mth Booster dose should be given at 12 mth w/ at least 2 mth interval after primary dose. Childn from 12 mth Booster dose is not routinely administered, however may be given to subject previously vaccinated w/ Nimenrix, other conjugated or plain polysaccharide meningococcal vaccines.
Contraindications
Hypersensitivity to the vaccine or to any excipients.
Special Precautions
Not to be administered intravascularly, intradermally or SC. Not as substitute for tetanus immunization. Postpone vaccination in subjects w/ acute severe febrile illness. Thrombocytopenia or any coagulation disorder; syncope; anatomic or functional asplenia eg, sickle cell disease. Patients receiving immunosuppressants or w/ immunodeficiency; complement deficiencies & receiving treatment inhibiting terminal complement activation ie, eculizumab. Avoid injury from faints. Pregnancy & lactation.
Adverse Reactions
Loss of appetite; irritability; drowsiness, headache; fever, inj site swelling, pain & redness, fatigue. GI symptoms eg, diarrhoea, vomiting, nausea; inj site haematoma.
Drug Interactions
Adequate response may not be elicited w/ immunosuppressants.
MIMS Class
Vaccines, Antisera & Immunologicals
ATC Classification
J07AH08 - meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugated ; Belongs to the class of meningococcal bacterial vaccines.
Presentation/Packing
Form
Nimenrix vaccine (inj) (vial & pre-filled syringe) 5 mcg/0.5 mL
Packing/Price
(+ solvent) 0.5 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in